"Sofosbuvir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.
| Descriptor ID |
D000069474
|
| MeSH Number(s) |
D03.383.742.686.850.877.500 D13.695.740.850.877.500 D13.695.827.919.877.500
|
| Concept/Terms |
Sofosbuvir- Sofosbuvir
- 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester
PSI 7977- PSI 7977
- 7977, PSI
- PSI7977
- PSI-7977
|
Below are MeSH descriptors whose meaning is more general than "Sofosbuvir".
Below are MeSH descriptors whose meaning is more specific than "Sofosbuvir".
This graph shows the total number of publications written about "Sofosbuvir" by people in this website by year, and whether "Sofosbuvir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 2 | 2 | 4 |
| 2018 | 0 | 2 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sofosbuvir" by people in Profiles.
-
Long-term efficacy and safety of sofosbuvir-based direct-acting antiviral regimens in paediatric patients with hepatitis C virus infection: an international registry study. Lancet Child Adolesc Health. 2025 04; 9(4):248-254.
-
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
-
Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on?dolutegravir-based antiretroviral therapy. J Viral Hepat. 2023 09; 30(9):740-745.
-
High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus. Eur J Gastroenterol Hepatol. 2022 10 01; 34(10):1098-1101.
-
Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis. Nephrology (Carlton). 2022 Jan; 27(1):82-89.
-
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology. 2021 12; 74(6):2952-2964.
-
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis. Liver Int. 2021 04; 41(4):705-709.
-
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat. 2021 02; 28(2):260-267.
-
Successful treatment of resistant HCV in a patient with Child-Pugh B cirrhosis using sofosbuvir and glecaprevir/pibrentasvir. BMJ Case Rep. 2020 Jul 05; 13(7).
-
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. Am J Gastroenterol. 2019 02; 114(2):250-257.